Ortem(Ortem) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域

肿瘤消化系统疾病皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

克罗恩病藏毛性窦道

原研机构

S.L.A. Pharma AG

在研机构-

非在研机构

S.L.A. Pharma AG

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 Ortem 相关的临床结果

登录后查看更多信息

100 项与 Ortem 相关的转化医学

登录后查看更多信息

100 项与 Ortem 相关的专利（医药）

登录后查看更多信息

1

项与 Ortem 相关的文献（医药）

2013-12-01·Transplantation Proceedings4区 · 医学

Is “Intra–operating Room” Thromboelastometry Useful in Liver Transplantation? A Case-Control Study in 303 Patients

4区 · 医学

Article

作者: J. Padillo ; C. Bernal ; J. Serrano ; G. Suárez ; P. Mellado ; L.M. Marín ; A. León ; M.-Á. Gómez ; C. Cepeda ; J.-M. Álamo

Coagulation monitoring during liver transplantation (LT) is, even today, fundamental to reduce blood loss during surgery. Thromboelastometry (TEM) is a proven technique for controlling the various parameters that influence coagulation. However, there are no studies linking "intra-operating room" TEM (orTEM) with LT outcomes. We describe a case-control study in 303 liver graft recipients analyzing variables associated with operative complications and long-term LT outcomes. The results showed that orTEM reduced the use of blood products in patients with Model for End-Stage Liver Disease scores of ≥ 21, retransplantation, and high surgical difficulty and important intraoperative bleeding. In addition, results in survival and postoperative complications were better when orTEM was used. In conclusion, we confirm that use of orTEM is associated with less use of blood products and a lower rate of complications after LT.

100 项与 Ortem 相关的药物交易

登录后查看更多信息